Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal

References

• Van der ZwanSMDe MatteoRPGastrointestinal stromal tumor: 5 years laterCancer20051031781178816136600
   PubMed Web of Science ®Google Scholar
• MucciariniCRossiGBertoliniFIncidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer2007723018096058
   PubMed Web of Science ®Google Scholar
• NilssonBBummingPMeis-KindblomJMGstrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinibmesylate era- a population based study in western SwedenCancer200510382182915648083
   PubMed Web of Science ®Google Scholar
• SteigenSEEideRJTrends in incidence and surzvival ofmesenchymal neoplasm of the digestive tract within a defined population of northern NorwayAPMIS200611419220016643186
   PubMed Web of Science ®Google Scholar
• PidhoreckyICheneyRTKraybillWGGibbsJFGastrointestinal stromal tumors: current diagnosis, biologic behaviour, and managementAnn Surg Oncol2000770571211034250
   PubMed Web of Science ®Google Scholar
• CorlessCLHeinrichMCMolecular pathobiology of gastrointestinal stromal sarcomasAnnu Rev Pathol2008355758618039140
   PubMed Web of Science ®Google Scholar
• D’AmatoGSteinertDMMcAuliffeJCTrentJCUpdate on thebiology and therapy of gastrointestinal stromal tumorsCancer Control200512445615668652
   PubMedGoogle Scholar
• ChompretAKannengiesserCBarroisMPDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumorGastroenterology200412631832114699510
   PubMed Web of Science ®Google Scholar
• NishidaTHirotaSTaniguchiMFamilial gastrointestinal stromal tumours with germline mutation of the KIT geneNat Genet1998193233249697690
   PubMed Web of Science ®Google Scholar
• DemetriGDBenjaminRSBlnackeCDNCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelinesJ Natl Compr Cancer Netw20075Suppl 2S1S29
   PubMedGoogle Scholar
• DeMatteoRPlewisJJLeungDTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survivalAnn Surg2000213515810636102
   PubMed Web of Science ®Google Scholar
• DeMatteoRPGoldJSSaranLTumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)Cancer200811260861518076015
   PubMed Web of Science ®Google Scholar
• PlaatBEHollemaHMolenaarWMSoft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in the clinical outcome and expression of multidrug resistance proteinsJ Clin Oncol2000183211322010986053
   PubMed Web of Science ®Google Scholar
• HsuKHYangTMShanYSLinPWTumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumorAm J Surg200719414815217618793
   PubMed Web of Science ®Google Scholar
• FletcherCDBermanJJCorlessCDiagnosis of gastrointestinal stromal tumors: a consensus approachHum Pathol20023345946512094370
   PubMed Web of Science ®Google Scholar
• MiettinenMSobinLHLasotaJGastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-upAm J Surg Pathol200529526815613856
   PubMed Web of Science ®Google Scholar
• BlankeCDDemetriGDvon MehrenMLong-term results from a randomized phase II trial of standard versus versus higher-dose imatinib mesylate for patients with unresectable gastrointestinal stromal tumors expressing KITJ Clin Oncol20082662062518235121
   PubMed Web of Science ®Google Scholar
• VerweijJvan OosteromABlayJYImatinib mesylate (STI 571 Glivec®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyEur J Cancer2003392006201112957454
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJprogression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet20043641127113415451219
   PubMed Web of Science ®Google Scholar
• DemetriGDven MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med200234747248012181401
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMMOwzarKRnakinCComparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta analysis base don 1,640 patients (pts)J Clin Oncol (Meeting Abstracts)20072518 Suppl10004
   Web of Science ®Google Scholar
• Van GlabekkeMVerweijJCasaliPGInitial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors : a European organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group studyJ Clin Oncol2005235795580416110036
   PubMed Web of Science ®Google Scholar
• CasaliPGJostLReichardtPSchlemmerMBlayJYfor the ESMO Guidelines working GroupGastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment, and follow upAnn Oncol200920Suppl 4646719454466
   PubMed Web of Science ®Google Scholar
• JudsonIGastrointestinal stromal tumour (GIST): biology and treatmentAnn Oncol200213Suppl 428728912401703
   PubMed Web of Science ®Google Scholar
• GoldJSDeMatteoRPCombined surgical and molecular therapy: the gastrointestinal stromal tumor modelAnn Surg200624417618416858179
   PubMed Web of Science ®Google Scholar
• PengBLlyodPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinet20054487989416122278
   PubMed Web of Science ®Google Scholar
• Novartis Europharm LimitedProduct information (EU): Glivec® (imatinib mesylate) tablets 100 mg and 400 mg http://www.emea.eu.int/. Accessed Jan 22, 2007.
   Google Scholar
• AsifMSiddiquiAScottLJImatinib. A Review of its use in the management of gastrointestinal stromal tumorsDrugs20076780582017385949
   PubMed Web of Science ®Google Scholar
• DemetriGDBenjaminRSBlankeCDNCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)–expansion and update of NCCN Clinical Practice GuidelinesJ Natl Compr Canc Netw20042Suppl 1S1S2619791422
   PubMedGoogle Scholar
• ZalcbergJRVerweijJCasaliPGOutcome of patients with advanced gastro-intestinal stromal tumours crossing-over to a daily imatinib dose of 800 mg after progression of 400 mgEur J Cancer2005411751175716098458
   PubMed Web of Science ®Google Scholar
• DeMatteoRPAntonescuCRChadaramVAdjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST). 38th Annual Meeting of the ASCO. Orlando, FL 2002J Clin Oncol2002Suppl Abstract 1610.
   Google Scholar
• DeMatteoRP2008 GastroIntestinal Cancers Symposium Abstract 8 (2008).
   Google Scholar
• NilssonBSjolundKKindblomLGMeis-KindblomJMBummingPNilssonOAdjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)Br J Cancer2007961656165817533389
   PubMed Web of Science ®Google Scholar
• BlayJYBonvalotSCasaliPGGIST consensus meeting panel-list. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMOAnn Oncol20051656657815781488
   PubMed Web of Science ®Google Scholar
• CasaliPGJostLReichardtPSchlemmerMBlayJYon behalf of the ESMO Guidelines Working GroupGastrointestinal stromal tumors.: ESMO clinical recommendations for diagnosis, treatment, and follow-upAnn Oncol200819Suppl II3538
   Web of Science ®Google Scholar
• DeMatteoRPOwzarKMakiRAdjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely resected localized primarygastrointestinale stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001J Clin Oncol (Meeting Abstracts)20072518 Suppl10079
   Google Scholar
• DeMatteoRPBallmanKVAntonescuCRMakiRGPistersPWDemetriGDAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialLancet20093731097110419303137
   PubMed Web of Science ®Google Scholar
• BlayJYLe CesneARay-CoquardBuiBDuffaudFProspective multicentric randomized phase III of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond one year: the French Sarcoma GroupJ Clin Oncol2007251107111317369574
   PubMed Web of Science ®Google Scholar
• Le CesneARay-CoquardIBuiBContinuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma GroupJ Clin Oncol (Meeting Abstracts)20072518 Suppl10005
   Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosisArch Pathol Lab Med20061301466147817090188
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: pathology and prognosis at different sitesSemin Diagn Pathol2006237983
   Web of Science ®Google Scholar
• JoensuuHRisk stratification of patients diagnosed with gastrointestinal stromal tumorHum Pathol2008391411141918774375
   PubMed Web of Science ®Google Scholar
• MartinJPovedaALlombart-BoschADeletions affecting codons 557–558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors. A study by the Spanish group for sarcoma research (GEIS)J Clin Oncol2005236190619816135486
   PubMed Web of Science ®Google Scholar
• MiettinenMEl-RifaiWHL SobinLLasotaJEvaluation of malignancy and prognosis of gastrointestinal stromal tumors: a reviewHum Pathol20023347848312094372
   PubMed Web of Science ®Google Scholar
• HuangHYLiCFHuangWWA modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcomeSurgery200714174875617560251
   PubMed Web of Science ®Google Scholar
• GohBKChowPKYapWMWhich is the optimal risk straficitation system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors, and proposal for a modified Armed Forces Institute of Pathology risk criteriaAnn Surg Oncol2008152153216318546045
   PubMed Web of Science ®Google Scholar
• GoldJGonenMGutierezABrotoXMGacia-del-MutoXSmyrkTdevelopment and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastro-intestinal stromal tumour: a retrospective analysisLancet Oncol20091011 [Epub ahead of print].
   Web of Science ®Google Scholar
• Debiec-RichterMSciotRLe CesneAKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer2006421093110316624552
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLRankinCPDGFRA activating mutations in gastrointestinal stromal tumorsScience200329970871012522257
   PubMed Web of Science ®Google Scholar
• CorlessCLSchroederAGriffithDPDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vivo sensitivityJ Clin Oncol20052323572364
   Web of Science ®Google Scholar